Sodium butyrate
(Synonyms: 丁酸钠) 目录号 : GC15857
A short-chain fatty acid and HDAC inhibitor
Cas No.:156-54-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
2 adenoma-derived cell lines (AA/Cl and RG/C2) |
|
Preparation method |
The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
1 ~ 4 mM; 4 days |
|
Applications |
In RG/C2 cells, Sodium Butyrate at the concentrations of 2 mM and above reduced the attached-cell yield to approximately 50% of the control, and significantly increased the proportion of floating cells. It was demonstrated that the increase in the percentage of floating cells was attributed to the induction of apoptosis and not simply due to increased necrosis. Compared with RG/C2 cells, AA/Cl cells were more sensitive to Sodium Butyrate. |
| Animal experiment [2]: | |
|
Animal models |
An R6/2 transgenic mouse model of Huntington's disease (HD) |
|
Dosage form |
100, 200, 400, 600, 1200, 5000 and 10,000 mg/kg; i.p.; q.d. |
|
Applications |
In an R6/2 transgenic mouse model of HD, Sodium Butyrate significantly extended survival in a dose-dependent manner, improved body weight and motor performance, as well as delayed the neuropathological sequelae. Moreover, Sodium Butyrate increased the level of histone and specificity protein-1 acetylation, and protected against 3-nitropropionic acid-induced neurotoxicity. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Hague A1, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer. 1993 Sep 30;55(3):498-505. [2]. Ferrante RJ1, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003 Oct 15;23(28):9418-27. |
|
Sodium butyrate is a short chain fatty acid that has effects at the molecular, cellular, and tissue level. It has long been known as an inhibitor of histone deacetylases (HDACs).[1],[2] In cells, this alters the expression of a select group of genes containing butyrate response elements and may also involve Sp1/Sp3 binding sites.[3] Sodium butyrate also induces growth arrest, differentiation and apoptosis in cancer cells, primarily through its effects on HDAC activity.[4] In addition, it suppresses inflammation, in part by reducing the expression of pro-inflammatory cytokines, including interferon-γ, interleukin (IL)-6, and IL-1β.[5]
Reference:
[1]. Boffa, L.C., Vidali, G., Mann, R.S., et al. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. The Journal of Biological Chemisty 253(10), 3364-3366 (1978).
[2]. Sealy, L., and Chalkley, R. The effect of sodium butyrate on histone modification. Cell 14, 115-121 (1978).
[3]. Davie, J.R. Inhibition of histone deacetylase activity by butyrate. Journal of Nutrition 133, 2485-2493 (2003).
[4]. Monneret, C. Inhibition of histone deacetylase activity by butyrate. European Journal of Medicinal Chemistry 40, 1-13 (2005).
[5]. Joseph, J., Mudduluru, G., Antony, S., et al. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23, 6304-6315 (2004).
| Cas No. | 156-54-7 | SDF | |
| 别名 | 丁酸钠 | ||
| 化学名 | sodium;butanoate | ||
| Canonical SMILES | CCCC(=O)[O-].[Na+] | ||
| 分子式 | C4H7NaO2 | 分子量 | 110.09 |
| 溶解度 | ≥ 4mg/mL in Water | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 9.0835 mL | 45.4174 mL | 90.8348 mL |
| 5 mM | 1.8167 mL | 9.0835 mL | 18.167 mL |
| 10 mM | 0.9083 mL | 4.5417 mL | 9.0835 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。